Reuters logo
BRIEF-Orexigen Therapeutics announces commercialization, distributorship agreement with Biologix FZCO for contrave for 10 countries in the Middle East
December 19, 2016 / 1:22 PM / a year ago

BRIEF-Orexigen Therapeutics announces commercialization, distributorship agreement with Biologix FZCO for contrave for 10 countries in the Middle East

Dec 19 (Reuters) - Orexigen Therapeutics Inc :

* Agreement covers ten countries in middle east

* Orexigen therapeutics-under terms of deal, Biologix responsible for obtaining regulatory approvals, local product registrations in each of 10 countries

* Biologix expects contrave to be available for patients in some countries starting in Q3 of 2017

* Press release - orexigen therapeutics announces commercialization and distributorship agreement with biologix fzco for contrave (naltrexone hcl / bupropion hcl prolonged release) for ten countries in the middle east Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below